Kubota Pharmaceutical Holdings Co (TSE:4596) Research & Development: 円211.86 Mil (TTM As of Mar. 2026)


TSE:4596 Kubota Pharmaceutical Holdings Co Ltd TSE:4596
46 GF Score
Price 円56.00
GF Value 円39.87
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Kubota Pharmaceutical Holdings Co Research & Development?

Kubota Pharmaceutical Holdings Co TSE:4596 46 Research & Development is 円211.86 Mil as of Mar. 2026. GuruFocus rates TSE:4596 with a GF Score™ of 46/100 and a GF Value™ of 円39.87 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Kubota Pharmaceutical Holdings Co's Research & Development for the three months ended in Mar. 2026 was 円139.33 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was 円211.86 Mil.

Kubota Pharmaceutical Holdings Co  (TSE:4596) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Kubota Pharmaceutical Holdings Co Research & Development Related Terms

Kubota Pharmaceutical Holdings Co Research & Development Historical Data

* Premium members only.

The historical data trend for Kubota Pharmaceutical Holdings Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kubota Pharmaceutical Holdings Co Research & Development Chart

Kubota Pharmaceutical Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,040.67 1,512.87 788.79 543.84 310.55

Kubota Pharmaceutical Holdings Co Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 71.06 72.52 0.00 139.33
TSE:4596
46GF Score
Kubota Pharmaceutical Holdings Co Ltd TSE:4596
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kubota Pharmaceutical Holdings Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円211.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円211.86 Mil mean?
Kubota Pharmaceutical Holdings Co (TSE:4596) has a Research & Development of 円211.86 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Kubota Pharmaceutical Holdings Co and its competitors.
Is Kubota Pharmaceutical Holdings Co's Research & Development too high?
Kubota Pharmaceutical Holdings Co's current Research & Development is 円211.86 Mil. Overall, Kubota Pharmaceutical Holdings Co has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kubota Pharmaceutical Holdings Co's Research & Development compare to VRTX and REGN?
Kubota Pharmaceutical Holdings Co's Research & Development of 円211.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Kubota Pharmaceutical Holdings Co and its competitors. Kubota Pharmaceutical Holdings Co's current Research & Development is 円211.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kubota Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Kubota Pharmaceutical Holdings Co (TSE:4596) is currently considered Significantly Overvalued. The stock's GF Value™ is 円39.87, compared to a current price of 円56.00 — trading 40.5% above its estimated fair value. The current Research & Development is 円211.86 Mil. Kubota Pharmaceutical Holdings Co's overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Kubota Pharmaceutical Holdings Co (TSE:4596), the current Research & Development is 円211.86 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kubota Pharmaceutical Holdings Co (TSE:4596) Overvalued in 2026?

Based on GuruFocus' analysis, Kubota Pharmaceutical Holdings Co stock appears to be overvalued. The current stock price of 円56.00 is trading 40.5% above its estimated GF Value™ of 円39.87. GuruFocus considers Kubota Pharmaceutical Holdings Co to be Significantly Overvalued.

Key valuation signals for TSE:4596:

  • Research & Development: 円211.86 Mil
  • GF Value™: 円39.87 vs. price of 円56.00 (40.5% above fair value)
  • GF Score™: 46/100 with 2 warning signs

No single metric tells the full story. See the TSE:4596 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kubota Pharmaceutical Holdings Co Business Description

Address 1-15-37 Minami-Aoyama, Minato-ku, Tokyo, JPN, 107-0062
Kubota Pharmaceutical Holdings Co Ltd is a Japanese company providing portfolio of drugs and devices to preserve and restore millions of people. It identifies and develops therapeutics to treat the opthalmic disorder and operations incidental or related thereto. Its pipeline products include VCM-Emixustat HCI, Lanosterol and Optogenetics.
46GF Score

Get the complete analysis for TSE:4596

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円56.00
Price
円39.87
GF Value